Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant pleural mesothelioma

P Baas1, H Schouwink, F A Zoetmulder

  • 1Division of Medical Oncology and Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. baas@nki.nl

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|April 29, 1998
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study.

ESMO real world data and digital oncology·2026
Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026
Same author

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Immuno-oncology technology·2025
Same author

Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA.

ESMO open·2025
Same author

Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.

Lung cancer (Amsterdam, Netherlands)·2024
Same author

First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?

Lung cancer (Amsterdam, Netherlands)·2024
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles